V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Alkermes Executive Compensation (FY25)

ALKS · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): May 20, 2026
383 figures on this page: 373 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
Richard Pops was paid $7,915,081 in total compensation as Chief Executive Officer and Chairman of the Board for fiscal 2025, and for fiscal 2025, the company reported a chief executive pay ratio of 30:1, against median employee compensation of $266,757. Meanwhile, the say-on-pay proposal drew 98.7% of votes cast for or against in favor at the meeting held May 20, 2026 for fiscal 2025. Separately, the disclosed peer group includes Acadia Pharmaceuticals, Axsome Therapeutics, BioMarin Pharmaceutical, Blueprint Medicines and Exelixis, among others, and for fiscal 2025, the company reported 6 named executive officers.
Chief executive, fiscal 2025
◇
Richard Pops
Median of the other named officers
$3,617,908
5 officers, excluding the chief executive
Latest say-on-pay support
=
May 20, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Richard Pops: $10,131,193 → $7,915,081 (21.9% lower)
Say-on-pay support: 98.7% → 98.7% (0.0 points higher)
CEO pay ratio: 45:1 → 30:1 (33.3% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Alkermes' chief executive and what were they paid?
Richard Pops was paid $7,915,081 in total compensation as Chief Executive Officer and Chairman of the Board for fiscal 2025. Pops' total was 21.9% lower than the $10,131,193 reported for fiscal 2024.
What was Alkermes' say-on-pay result?
The say-on-pay proposal drew 98.7% of votes cast for or against in favor at the meeting held May 20, 2026 for fiscal 2025.
Which companies are in Alkermes' peer group?
The disclosed peer group includes Acadia Pharmaceuticals, Axsome Therapeutics, BioMarin Pharmaceutical, Blueprint Medicines and Exelixis, among others.
What is Alkermes' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 30:1, against median employee compensation of $266,757.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Gaffin
Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary
◇—◇◇◇—◇— not reconciled
Richard Pops
Chief Executive Officer and Chairman of the Board
◇—◇◇◇—◇— not reconciled
Craig Hopkinson
Executive Vice President, Research and Development and Chief Medical Officer
◇—◇◇◇—◇— not reconciled
Blair Jackson
Executive Vice President, Chief Operating Officer
◇—◇◇◇—◇— not reconciled
Iain Brown
Senior Vice President, Chief Financial Officer
◇—◇◇◇—◇— not reconciled
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard F. Pops
Chief Executive Officer and Chairman of the Board
◇—◇◇◇—◇◇
Blair C. Jackson
Executive Vice President, Chief Operating Officer and Chief Risk Officer
◇—◇◇◇—◇◇
Craig C. Hopkinson
Executive Vice President, Research and Development and Chief Medical Officer
◇—◇◇◇—◇◇
David J. Gaffin
Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary
◇—◇◇◇—◇◇
Iain M. Brown
Senior Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard F. Pops
Chief Executive Officer and Chairman of the Board
◇—◇◇◇—◇◇
Blair C. Jackson
Executive Vice President, Chief Operating Officer and Chief Risk Officer; Interim Principal Financial Officer
Served on an interim basis
◇—◇◇◇—◇◇
Craig C. Hopkinson
Executive Vice President, Research and Development and Chief Medical Officer
◇—◇◇◇—◇◇
David J. Gaffin
Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary
◇—◇◇◇—◇◇
C. Todd Nichols
Senior Vice President, Chief Commercial Officer
◇—◇◇◇—◇◇
Iain M. Brown
Senior Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard Pops
Chief Executive Officer and Chairman of the Board
◇——◇◇—◇◇
Blair Jackson
Executive Vice President, Chief Operating Officer and Chief Risk Officer; Former Interim Principal Financial Officer
Departed during or after this year
Served on an interim basis
◇—◇◇◇—◇◇
Joshua Reed
Senior Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Craig Hopkinson
Executive Vice President, Research and Development and Chief Medical Officer
◇—◇◇◇—◇◇
David Gaffin
Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary
◇—◇◇◇—◇◇
C. Todd Nichols
Senior Vice President, Chief Commercial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Blair C. JacksonOPTION◇——◇—◇◇
Blair C. JacksonRSU◇——◇——◇
C. Todd NicholsOPTION◇——◇—◇◇
C. Todd NicholsRSU◇——◇——◇
Craig C. HopkinsonRSU◇——◇——◇
Craig C. HopkinsonOPTION◇——◇—◇◇
David J. GaffinRSU◇——◇——◇
David J. GaffinOPTION◇——◇—◇◇
Joshua ReedOPTION◇——◇—◇◇
Joshua ReedRSU◇——◇——◇
Richard F. PopsOPTION◇——◇—◇◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
David GaffinRSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Craig HopkinsonRSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Blair JacksonRSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
Richard PopsOption◇—◇—
Option◇—◇—
PSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
PSU◇◇——
RSU◇◇——
C. Todd NicholsOption◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Joshua ReedRSU◇◇——
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Frank Anders Wilson
Lead independent director
◇◇◇———◇
David A. Daglio, Jr
◇◇◇———◇
David A. Daglio Jr
◇◇◇———◇
Emily Peterson Alva
◇◇◇———◇
Brian P. McKeon
◇◇◇———◇
Shane M. Cooke
◇◇◇———◇
Nancy L. Snyderman, M.D
◇◇◇———◇
Christopher I. Wright, M.D., Ph.D
◇◇◇———◇
Nancy S. Lurker
◇◇◇———◇
Richard B. Gaynor, M.D
◇◇◇———◇
Cato T. Laurencin, M.D., Ph.D
◇◇◇———◇
Richard F. Pops served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Board meeting fee◇
Equity is delivered as RSUs and Stock Options (50/50 split).
Stock ownership guideline: 3x annual retainer

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Acadia Pharmaceuticals ACAD
  • Axsome Therapeutics AXSM
  • BioMarin Pharmaceutical BMRN
  • Blueprint Medicines BPMC
  • Exelixis EXEL
  • Halozyme Therapeutics HALO
  • Harmony Biosciences HRMY
  • Incyte INCY
  • Intra-Cellular Therapies ITCI
  • Ionis Pharmaceuticals IONS
  • Jazz Pharmaceuticals JAZZ
  • Neurocrine Biosciences NBIX
  • PTC Therapeutics PTCT
  • Sarepta Therapeutics SRPT
  • Ultragenyx Pharmaceutical RARE
  • United Therapeutics UTHR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 20, 2026=◇◇◇
2024May 21, 2025=◇◇◇
2023May 31, 2024=◇◇◇
2022June 29, 2023=◇◇◇
2021July 7, 2022=◇◇◇
2020June 14, 2021=◇◇◇
2019May 20, 2020=◇◇◇
2018May 22, 2019=◇◇◇
2017May 23, 2018=◇◇◇
2016May 24, 2017=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Alkermes files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Alkermes disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Alkermes sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Alkermes' disclosed peer group is defensible, who names Alkermes back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
383 figures on this page: 373 cited to the filing that reported them, 10 calculated from figures it prints.
373 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001193125-26-232584
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-143977
    2025 Director Compensation Table · ALKERMES PLC · Grants of Plan-Based Awards · Key Features of Our Non-Employee Director Compensation Program · and 2 more sections
  3. 0000950170-25-075783
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000950170-25-051644
    Summary Compensation Table
  5. 0000950170-24-067296
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000950170-24-044420
    Summary Compensation Table
  7. 0000950170-23-031901
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001564590-22-025465
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001564590-21-032786
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001564590-20-026406
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001564590-19-020161
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001520262-18-000029
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001520262-17-000029
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Alkermes executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ALKS (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Alkermes and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Alkermes discloses

The companies named in ALKS's own disclosed peer group.

Acadia PharmaceuticalsBioMarin PharmaceuticalExelixisHalozyme TherapeuticsIncyteIonis PharmaceuticalsJazz PharmaceuticalsNeurocrine BiosciencesPTC TherapeuticsSarepta TherapeuticsUltragenyx PharmaceuticalUnited Therapeutics

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy